RecallRadar

FDA Drug recall D-0518-2024

Cefdinir for Oral Suspension USP, 250 mg/5 mL, packaged in a 60 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimor…

On 2024-06-05 the FDA classified a Class II recall of Cefdinir for Oral Suspension USP, 250 mg/5 mL, packaged in a 60 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimor… by Lupin Pharmaceuticals, citing defective container: lack of seal integrity.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0518-2024
ClassificationClass II
Statusterminated
Initiated2024-05-08
Published2024-06-05
Last updated2026-09-13 11:52 UTC
CompanyLupin Pharmaceuticals
DistributionUS

Product

Cefdinir for Oral Suspension USP, 250 mg/5 mL, packaged in a 60 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, MD 21202, Manufactured by: Lupin Limited, Mandideep, 462 046 India, NDC 68180-723-04

Reason

Defective container: lack of seal integrity.

Identifiers

ndc68180-722-20
ndc68180-722-10
ndc68180-722-04
ndc68180-722-05
ndc68180-723-20
ndc68180-723-10
ndc68180-723-04
ndc68180-723-05
code_infoLot #F305184, F305185, F305186, Exp 7/31/ 2025

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0518-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.